Miltefosine

Chemical formula: C₂₁H₄₆NO₄P  Molecular mass: 407.576 g/mol  PubChem compound: 3599

Active ingredient description

Miltefosine has a marked direct antileishmanial activity in vitro and in animal models. Leishmania donovani was the most sensitive species in promastigote and amastigote test systems.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
P01CX04 Miltefosine P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01C Agents against leishmaniasis and trypanosomiasis → P01CX Other agents against leishmaniasis and trypanosomiasis
Discover more medicines within P01CX04

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
IMPAVIDO Hard capsules MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 58066-85-6
DrugBank Drug: DB09031
KEGG Drug: D02494
PubChem Compound: 3599
RxNorm Ingredient: 1494066
SNOMED-CT Concept: 713642004
Miltefosine (substance)
UNII Identifier: 53EY29W7EC
MILTEFOSINE

Medicines

Miltefosine is an active ingredient of these brands:

Lithuania (LT)

South Africa (ZA)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.